Nuvectis Pharma, Inc. today announced a publication in the Journal of Experimental Medicine (“JEM”) for NXP900 in an in-vivo model of metastatic castration resistant prostate cancer.
FORT LEE, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a publication in the Journal of Experimental Medicine (“JEM”) for NXP900 in an in-vivo model of metastatic castration resistant prostate cancer (“mCRPC”) with acquired resistance to enzalutamide, the active ingredient in XTANDI®.
“This publication adds encouraging new data to the substantial body of evidence supporting the clinical potential of NXP900 (referred to as eCF506 in the publication),” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, “Led by top scientists and published in a leading scientific journal, the research, which highlights NXP900’s potential to reverse XTANDI® resistance when dosed in combination with XTANDI®, also highlights the relationship between the effects seen in the enzalutamide-resistant mCRPC model to NXP900’s mechanism of action. Based on all the evidence generated to date, we believe that NXP900 has the potential to become a best-in-class SRC/YES1 kinase inhibitor with potential utility in a range of solid tumor cancers and we look forward to unlocking its therapeutic potential in the clinic.”
The publication, titled “Macrophages Promote Anti-Androgen Resistance in Prostate Cancer Bone Disease”, can be found here.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical stage, oral small molecule that has demonstrated robust preclinical anti-tumor activity in ARID1a-mutated xenograft models of ovarian and gastric carcinomas. NXP800 was granted Fast Track Designation by the United States Food and Drug Administration for the treatment of platinum-resistant, ARID1a-mutated, ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with a phase 1 clinical trial pending commencement.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, and other factors that are difficult to predict and include statements regarding the preclinical data generated to date, and the clinical expectations for NXP800 and NXP900, including the timing for the completion of the Phase 1a study and commencement of the Phase 1b study for NXP800, the IND submission and commencement of the Phase 1 program for NXP900, statements regarding NXP800’s potential ability to become a therapeutic option for the treatment of ARID1a-mutated ovarian carcinoma, and potentially other cancer indications, and NXP900’s potential to become a therapeutic treatment option for the treatment of metastatic castration resistant prostate cancer. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled “Risk Factors” in the 2021 Form 10-K filed with the Securities and Exchange Commission (“SEC”). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contact:
Ron Bentsur, Chairman and CEO
Nuvectis Pharma, Inc.
IR Contact:
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
